CEL-SCI submits response to FDA's partial clinical hold of Multikine study in head and neck cancer

• CEL-SCI (CVM -1.8%) announces that it has submitted its response to the FDA regarding the partial clinical hold instituted in September on its Phase 3 study assessing Multikine (Leukocyte Interleukin, Injection) in patients with squamous cell carcinoma of the head and neck.
• The company has not disclosed the precise nature of the agency's action but it usually involves a safety signal of some kind.
• Previously: FDA places CEL-SCI's Multikine study in head and neck cancer on clinical hold; shares off 13% premarket (Sept. 27)